A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis [PDF]
Trials, 2023 Background Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a
A Dierig +24 more
doaj +14 more sources
In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China [PDF]
Infection and Drug Resistance, 2021 Xia Yu,* Fengmin Huo,* Fen Wang,* Shu’an Wen, Guanglu Jiang, Yi Xue, Lingling Dong, Liping Zhao, Rui Zhu, Hairong Huang National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Yu X +9 more
doaj +5 more sources
Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]
Frontiers in Medicine, 2022 ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang +10 more
doaj +2 more sources
Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection [PDF]
Scientific Reports, 2023 The prevalence of Mycobacterium avium complex-pulmonary disease (MAC-PD) has become a growing concern worldwide, and current treatments involving macrolides (clarithromycin [CLR] or azithromycin), ethambutol, and rifampicin have limited success ...
Ju Mi Lee +5 more
doaj +2 more sources
Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial [PDF]
Microbiology SpectrumMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a serious clinical challenge due to limited treatments and high mortality. We conducted both preclinical and clinical studies to assess the potential role of delpazolid in combination with ...
Kyung-Hwa Park +13 more
doaj +2 more sources
The pipeline of new molecules and regimens against drug-resistant tuberculosis [PDF]
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021 The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles.
Todd A. Black, Ulrike K. Buchwald
doaj +2 more sources
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]
PharmaceuticsMultidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen +4 more
doaj +2 more sources
Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones [PDF]
PharmaceuticalsIn the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of
Jessica Ceramella +9 more
doaj +2 more sources
Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects [PDF]
Molecules, 2021 This review covers the main aspects concerning the chemistry, the biological activity and the analytical determination of oxazolidinones, the only new class of synthetic antibiotics advanced in clinical use over the past 50 years.
Claudia Foti +3 more
doaj +2 more sources
Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, China [PDF]
PathogensOxazolidinones, novel synthetic antibacterials, inhibit protein biosynthesis and show potent activity against Gram-positive bacteria, including Mycobacterium tuberculosis (MTB).
Jinhui Dong +9 more
doaj +2 more sources